DOP2016000148A - Piperidiniltetrahidroquinolinas sustituidas - Google Patents

Piperidiniltetrahidroquinolinas sustituidas

Info

Publication number
DOP2016000148A
DOP2016000148A DO2016000148A DO2016000148A DOP2016000148A DO P2016000148 A DOP2016000148 A DO P2016000148A DO 2016000148 A DO2016000148 A DO 2016000148A DO 2016000148 A DO2016000148 A DO 2016000148A DO P2016000148 A DOP2016000148 A DO P2016000148A
Authority
DO
Dominican Republic
Prior art keywords
disorders
diabetic
prevention
peripheral
treatment
Prior art date
Application number
DO2016000148A
Other languages
English (en)
Inventor
Dieter Lang
Frank Wunder
Carsten Schmeck
Andreas Knorr
Gorden Redlich
Anja Buchmüller
Karen Engel
Becker-Pelster Eva María
Andreas Göller
Herbert Himmel
Raimund Kast
Hanna Tinel
Philipp Buchgraber
Volker Geiss
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of DOP2016000148A publication Critical patent/DOP2016000148A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRESENTE SOLICITUD SE RELACIONA CON NUEVAS PIPERIDINILTETRAHIDROQUINOLINAS SUSTITUIDAS, CON PROCESOS PARA SU PREPARACIÓN, CON SU USO PARA EL TRATAMIENTO Y/O PREVENCIÓN DE ENFERMEDADES Y CON SU USO PARA PREPARAR MEDICAMENTOS PARA EL TRATAMIENTO Y/O PREVENCIÓN DE ENFERMEDADES, EN PARTICULAR PARA EL TRATAMIENTO Y/O PREVENCIÓN DE MICROANGIOPATÍAS DIABÉTICAS, ÚLCERAS DIABÉTICAS DE LAS EXTREMIDADES, EN PARTICULAR PARA PROMOVER EL CURADO DE HERIDAS DE ÚLCERAS DE PIE DIABÉTICO, FALLA CARDIACA DIABÉTICA, TRASTORNOS CARDIACOS MICROVASCULARES CORONARIOS DIABÉTICOS, TRASTORNOS VASCULARES PERIFÉRICOS Y CARDIACOS, TRASTORNOS TROMBOEMBOLÍTICOS E ISQUEMIAS, TRASTORNOS DE LA CIRCULACIÓN PERIFÉRICA, FENÓMENO DE RAYNAUD, SÍNDROME DE CREST, TRASTORNOS MICROCIRCULATORIOS, CLAUDICACIÓN INTERMITENTE, Y NEUROPATÍAS PERIFÉRICAS Y AUTÓNOMAS.
DO2016000148A 2013-12-19 2016-06-17 Piperidiniltetrahidroquinolinas sustituidas DOP2016000148A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13198388 2013-12-19
EP14192878 2014-11-12

Publications (1)

Publication Number Publication Date
DOP2016000148A true DOP2016000148A (es) 2016-07-15

Family

ID=52102673

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2016000148A DOP2016000148A (es) 2013-12-19 2016-06-17 Piperidiniltetrahidroquinolinas sustituidas

Country Status (19)

Country Link
US (1) US9624198B2 (es)
EP (1) EP3083593A1 (es)
JP (1) JP2017501164A (es)
KR (1) KR20160098424A (es)
CN (1) CN105980374A (es)
AP (1) AP2016009303A0 (es)
AU (1) AU2014364735A1 (es)
CA (1) CA2934133A1 (es)
CR (1) CR20160277A (es)
CU (1) CU20160089A7 (es)
DO (1) DOP2016000148A (es)
EA (1) EA201691278A1 (es)
IL (1) IL246271A0 (es)
MX (1) MX2016008114A (es)
PE (1) PE20160842A1 (es)
PH (1) PH12016501146A1 (es)
SG (1) SG11201604949XA (es)
TN (1) TN2016000249A1 (es)
WO (1) WO2015091417A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201604978QA (en) * 2013-12-19 2016-07-28 Bayer Pharma AG Substituted piperidinyl-tetrahydroquinolines and their use as alpha-2c adrenoreceptor antagonists
CA3061444A1 (en) 2017-04-27 2018-11-01 Bayer Aktiengesellschaft Selective adrenoreceptor .alpha.2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad)
BR112021007830A2 (pt) * 2018-11-20 2021-08-03 Bayer Aktiengesellschaft antagonistas do adrenoceptor-alfa2 do subtipo c (al-fa-2c) para o tratamento da apneia do sono
WO2020165031A1 (de) * 2019-02-15 2020-08-20 Bayer Aktiengesellschaft Substituierte isochinolin-piperidinylmethanon-derivate
WO2020182018A1 (zh) * 2019-03-12 2020-09-17 四川科伦博泰生物医药股份有限公司 氮杂环化合物、其制备方法及用途
EP4076459B1 (en) * 2019-12-17 2026-04-29 Merck Sharp & Dohme LLC Prmt5 inhibitors
US12569481B2 (en) 2020-06-12 2026-03-10 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
CA3222626A1 (en) 2021-05-13 2022-11-17 Yunlong Song Compound having anti-tumor activity and use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1052224C (zh) 1993-04-07 2000-05-10 大塚制药株式会社 哌啶衍生物、含有它的外周血管舒张剂及其应用
CZ220498A3 (cs) 1996-01-17 1998-11-11 Novo Nordisk A/S Deriváty 1,2,4-thiadiazinu a 1,4-thiazinu, příprava a použití
AU757693B2 (en) 1997-07-16 2003-03-06 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
UA69420C2 (uk) 1998-10-06 2004-09-15 Янссен Фармацевтика Н.В. ТРИЦИКЛІЧНІ <font face="Symbol">D3</font>-ПІПЕРИДИНИ ЯК <font face="Symbol">a<sub></font>2</sub>-АНТАГОНІСТИ
PL203117B1 (pl) 1999-05-04 2009-08-31 Schering Corp Piperydynopiperydynowa pochodna użyteczna jako antagonista CCR5, zawierająca ją kompozycja farmaceutyczna i jej zastosowanie
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
US6444681B1 (en) 2000-06-09 2002-09-03 The Ohio State University Research Foundation Methods and compositions for treating Raynaud's Phenomenon and scleroderma
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
GB0108876D0 (en) 2001-04-09 2001-05-30 Novartis Ag Organic Compounds
AR036366A1 (es) 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
WO2004067513A1 (en) 2003-01-27 2004-08-12 Oy Juvantia Pharma Ltd Antagonists for alpha-2 adrenoceptors
AU2004285051A1 (en) * 2003-11-03 2005-05-12 Schering Corporation Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
EP1725235B1 (en) 2004-02-05 2009-04-15 Schering Corporation Piperidine derivatives useful as ccr3 antagonists
WO2006105304A2 (en) 2005-03-31 2006-10-05 Janssen Pharmaceutica N.V. Phenyl and pyridyl lta4h modulators
TW201024282A (en) * 2008-11-20 2010-07-01 Orion Corp New pharmaceutical compounds
AU2012232658B2 (en) 2011-03-22 2016-06-09 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof

Also Published As

Publication number Publication date
EA201691278A1 (ru) 2017-02-28
WO2015091417A1 (de) 2015-06-25
SG11201604949XA (en) 2016-07-28
US20160304491A1 (en) 2016-10-20
AP2016009303A0 (en) 2016-06-30
WO2015091417A8 (de) 2016-08-11
PH12016501146A1 (en) 2016-08-15
EP3083593A1 (de) 2016-10-26
MX2016008114A (es) 2017-01-20
PE20160842A1 (es) 2016-09-24
JP2017501164A (ja) 2017-01-12
CN105980374A (zh) 2016-09-28
TN2016000249A1 (en) 2017-10-06
CU20160089A7 (es) 2016-10-28
AU2014364735A1 (en) 2016-07-07
IL246271A0 (en) 2016-08-02
KR20160098424A (ko) 2016-08-18
US9624198B2 (en) 2017-04-18
CA2934133A1 (en) 2015-06-25
CR20160277A (es) 2016-10-14

Similar Documents

Publication Publication Date Title
DOP2016000149A (es) Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alfa-2c
CR20160277A (es) Piperidinil tetrahidroquinolinas sustituidas
CO7240369A2 (es) Ácido 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
MX389847B (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
BR112017023170A2 (pt) dispositivo de banho medicinal e seu uso
ITMI20120370A1 (it) Miscela antimicrobica e rivestimento per supportare la guarigione di ferite, che ha un effetto antimicrobico.
CL2013003003A1 (es) Uso de fórmula infantil que comprende al menos una fuente de proteínas, una fuente de lípidos, una fuente de carbohidratos, con 1,6-1,85 g/100 kcal que sirve para preparar un medicamento útil en la prevención de la presión sanguínea elevada o de las enfermedades cardiovasculares.
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
MX2020007462A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
CR20140473A (es) Compuestos de pirazol como inhibidores de sglt1
GT201300125A (es) 1h-pirazol-5-olato sódico sustituido
DOP2016000076A (es) Tienouracilcarboxamidas cíclicas y usos de las mismas
BR112018073355A2 (pt) gordura e seus usos médicos
EA201492154A1 (ru) Косметическая и/или фармацевтическая композиция для лечения воспаления кожи и связанных синдромов
CL2013000021A1 (es) Forma cristalina delta de la sal de arginina de perindoprilo; procedimiento de preparacion; composiciones farmaceuticas que la contienen; y su uso par el tratamiento de las enfermedades cardiovasculares, tales como hipertension arterial, insuficiencia cardiaca o enfermedad coronaria estable.
SE0401943D0 (sv) New use
MX2016003650A (es) Prostaglandina f2alfa y analogos de la misma para tratar la cicatrizacion cutanea atrofica.
CY1119117T1 (el) Δερμοπροστατευτικη και δερμο-εξισορροπητικη συνθεση
UA105127C2 (uk) Фармацевтична композиція у формі м&#39;якої лікарської форми з протизапальною, антимікробною та репаративною дією
IN2015KN00091A (es)
PE20180326A1 (es) Formulaciones que contienen diacereina y metodos que las utilizan para disminuir el nivel del acido urico en sangre
UA98844U (en) Method of treating and preventing of diseases by the use of a pharmaceutical composition comprising the co-crystal of choline hydrogen diacid
PL417551A1 (pl) Zastosowanie insuliny do leczenia stopy cukrzycowej w formie iniekcji bezpośredniej w chorą stopę
RU2012130739A (ru) Комбинированный лекарственный препарат, предназначенный для подготовки к диагностической или лечебной транспищеводной медицинской манипуляции